Josep Maria Llovet

Josep Maria Llovet

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Josep Maria Llovet

Liver Cancer Translational Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JLJosep M. Llovet
Josep M. Llovet
SRSergio Ricci
Sergio Ricci
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
PHPhilip Hilgard
Philip Hilgard
EGEdward Gane
Edward Gane
JBJordi Bruix
Jordi Bruix
No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand–foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)

1 July 2018 in Journal of Hepatology
Verified
Journal Article
Open access
PGPeter R. Galle
Peter R. Galle
AFAlejandro Forner
Alejandro Forner
JLJosep M. Llovet
Josep M. Llovet
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
FPFabio Piscaglia
Fabio Piscaglia
VVValérie Vilgrain
Valérie Vilgrain

21 January 2021 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
JLJosep M. Llovet
Josep M. Llovet
RKRobin Kate Kelley
Robin Kate Kelley
AVAugusto Villanueva
Augusto Villanueva
ASAmit G. Singal
Amit G. Singal
EPEli Pikarsky
Eli Pikarsky
RFRichard S. Finn
Richard S. Finn

19 February 2010 in Seminars in Liver Disease
Verified
Journal Article
Closed access
PDF file
RLRiccardo Lencioni
Riccardo Lencioni
JLJosep M Llovet
Josep M Llovet
The endpoint in cancer research is overall survival. Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used. Measurement of response rate in hepatocellular carcinoma (HCC) has become a controversial issue. The World Health Organization (WHO) criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Association for the Study of the Liver (EASL) to take into account treatment-induced tumor necrosis. Applying these guidelines, there was an association between response rate and outcome prediction. More recently, the Response Evaluation Criteria in Solid Tumors (RECIST) guideline was proposed as a method for measuring treatment response based on tumor shrinkage, which is a valuable measure of antitumor activity of cytotoxic drugs. This method was initially adopted by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for drug approval. However, anatomic tumor response metrics can be misleading when applied to molecular-targeted therapies or locoregional therapies in HCC. In 2008, a group of experts convened by the American Association for the Study of Liver Diseases (AASLD) developed a set of guidelines aimed at providing a common framework for the design of clinical trials in HCC and adapted the concept of viable tumor–tumoral tissue showing uptake in arterial phase of contrast-enhanced radiologic imaging techniques—to formally amend RECIST. These amendments conformed the AASLD-JNCI (Journal of the National Cancer Institute) guidelines and are summarized and clarified in the current article. They are referred to herein as the modified RECIST assessment (mRECIST). Further studies are needed to confirm the accuracy of this measurement compared with conventional gold standards such as pathologic studies of explanted livers.

1 March 2012 in The Lancet
Verified
Journal Article
Closed access
AFAlejandro Forner
Alejandro Forner
JLJosep M Llovet
Josep M Llovet
JBJordi Bruix
Jordi Bruix

1 December 2003 in The Lancet
Verified
Journal Article
Open access
JLJosep M Llovet
Josep M Llovet
ABAndrew Burroughs
Andrew Burroughs
JBJordi Bruix
Jordi Bruix
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of hepatitis B and C virus infection. Patients with cirrhosis are at the highest risk and should be monitored every 6 months. Surveillance can lead to diagnosis at early stages, when the tumour might be curable by resection, liver transplantation, or percutaneous treatment. In the West and Japan, these treatments can be applied to 30% of patients, and result in 5-year survival rates higher than 50%. Resection is indicated among patients who have one tumour and well-preserved liver function. Liver transplantation benefits patients who have decompensated cirrhosis and one tumour smaller than 5 cm or three nodules smaller than 3 cm, but donor shortage greatly limits its applicability. This difficulty might be overcome by living donation. Most HCC patients are diagnosed at advanced stages and receive palliative treatments, which have been assessed in the setting of 63 randomised controlled trials during the past 25 years. Meta-analysis shows that only chemoembolisation improves survival in well-selected patients with unresectable HCC.